Skip to content
DraconiticResearch
Search Sources API
186,631 studies31 sourcesUpdated 57 min ago
PreprintCC BY-NC-NDbioRxiv

Discontinuation of GLP-1RA Treatment Reinstates Binge-Like Eating and Drives Body Weight Past Pre-Treatment Levels in Mice

  • B. A. Hildebrandt1
  • S. E. Ahmari
  1. 1University of Pittsburgh School of Medicine
Read full textPDFDOICite

Abstract

We examined the impact of semaglutide treatment and discontinuation in a pre-clinical model for binge eating. Treatment reduced body weight and palatable food intake in mice with binge-like eating. Discontinuation reinstated binge-like eating and caused body weight to significantly exceed pre-treatment baseline, revealing specific binge-related risk when discontinuing GLP-1RAs.

Related

  1. AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis
    Matthias Augustin, Andreas Pinter, Silvia Sabatino +8
    Dermatology and TherapyPeer-reviewedCC BY-NC 4.0Full textImmunologyHAL
  2. Adjusted Comparative Treatment Persistence of IL-23p19 Versus IL-17 Pathway Inhibitors in Adults With Plaque Psoriasis: A Systematic Review and Exploratory Meta-analysis of Real-World Time-to-Discontinuation Estimates
    Deya S Migdady, Nooran Alshyyab, Hashem M Alkhalaileh +7
    CureusPeer-reviewedCC BYFull textImmunologyEurope PMCPMC
  3. Longitudinal treatment selection under irreversible discontinuation: History-aware prediction and trajectory-aware learning in peanut-allergy prevention
    R. Taub, T. Wasserman, Y. Savir
    bioRxivPreprintCC BY-NCFull textBioinformatics & computational biologybioRxiv
  4. Is it time for anti-CD20 discontinuation in multiple sclerosis? Cumulative risk or cumulative uncertainty
    Aurora Zanghì, Anneke van der Walt, Emanuele D’Amico
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossref
  5. Impact of renin-angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation
    Valentin Maisons, Margaux Costes-Albrespic, Sophie Liabeuf +10
    Clinical Kidney JournalPeer-reviewedCC BY 4.0Full textGeneral biologyGeneral medicineHAL

Cite

BibTeXRIS
BibTeX
@misc{hildebrandt2026discontinuation,
  title = {{Discontinuation of GLP-1RA Treatment Reinstates Binge-Like Eating and Drives Body Weight Past Pre-Treatment Levels in Mice}},
  author = {B. A. Hildebrandt and S. E. Ahmari},
  howpublished = {bioRxiv},
  year = {2026},
  month = nov,
  doi = {10.64898/2026.11.02.763781},
  url = {https://www.biorxiv.org/content/10.64898/2026.11.02.763781v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Discontinuation of GLP-1RA Treatment Reinstates Binge-Like Eating and Drives Body Weight Past Pre-Treatment Levels in Mice
AU  - B. A. Hildebrandt
AU  - S. E. Ahmari
PY  - 2026
DA  - 2026/11/02
PB  - bioRxiv
DO  - 10.64898/2026.11.02.763781
UR  - https://www.biorxiv.org/content/10.64898/2026.11.02.763781v1
AB  - We examined the impact of semaglutide treatment and discontinuation in a pre-clinical model for binge eating. Treatment reduced body weight and palatable food intake in mice with binge-like eating. Discontinuation reinstated binge-like eating and caused body weight to significantly exceed pre-treatment baseline, revealing specific binge-related risk when discontinuing GLP-1RAs.
ER  -